Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
22.47
-0.58 (-2.52%)
Oct 21, 2025, 3:29 PM EDT - Market open
Upstream Bio Revenue
Upstream Bio had revenue of $937.00K in the quarter ending June 30, 2025, with 83.73% growth. This brings the company's revenue in the last twelve months to $2.72M, up 22.60% year-over-year. In the year 2024, Upstream Bio had annual revenue of $2.37M, down -0.42%.
Revenue (ttm)
$2.72M
Revenue Growth
+22.60%
P/S Ratio
438.92
Revenue / Employee
$52,365
Employees
52
Market Cap
1.21B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.37M | -10.00K | -0.42% |
Dec 31, 2023 | 2.38M | 1.17M | 96.37% |
Dec 31, 2022 | 1.21M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionUPB News
- 21 days ago - Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress - GlobeNewsWire
- 6 weeks ago - Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum - GlobeNewsWire
- 6 weeks ago - Upstream Bio, Inc. - Special Call - Seeking Alpha
- 7 weeks ago - Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - GlobeNewsWire
- 7 weeks ago - Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) - GlobeNewsWire
- 2 months ago - Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress - GlobeNewsWire
- 3 months ago - Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) - GlobeNewsWire
- 4 months ago - Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor - GlobeNewsWire